ClinicalTrials.gg
RecruitingNCT07612267Updated Nov 4, 2026

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

A Phase 4 interventional study of Mirikizumab in Lactation and Inflammatory Bowel Disease, sponsored by Eli Lilly and Company. Recruiting at 20 sites in 7 countries. Open to female participants aged 3 Weeks and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Other

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
3 Weeks and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Breast Feeding with a site in United States — 44 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.

Planned enrollment
168th of 202
14 · median 83
Started
2026
with 13 others
Phase 4
14 of 251
4 open now
Primary completion
2028-09
later than 35 of 48 live
Registered
244th of 251
by date

Among the 251 studies in Breast Feeding with a site in United States, this one is the 168th largest by planned enrollment of the 202 interventional ones that give a count, is one of 14 that started in 2026, is one of 14 in phase 4, reaches primary completion later than 35 of the 48 other live ones, and was the 244th registered.

Breast Feeding

1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.

Browse Breast Feeding studies →

Open to participants now

44 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.

This study: 3 Weeks and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Breast Feeding with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication.

Participation in this study could last up to 94 days, including screening and follow-up period.

03

Conditions studied

  • Lactation
  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
3 Weeks and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study Participants:

  • Mothers who are at minimum 18 years of age and their infants who are at least 36 weeks gestation age at birth and at least 3 weeks old by Study Day 0
  • Multiple births may be allowed following discussion with the medical monitor.

Note: in the opinion of the healthcare practitioner (HCP), there are no infant or maternal issues that would preclude the mother participant or the infant from participation

  • Lactation history is well established, with the mother exclusively breastfeeding her infant
  • Mother participant is receiving mirikizumab therapeutically for an approved diagnosis (having received at least 2 doses of mirikizumab SC maintenance therapy every 4 weeks prior to study Day 0)
  • Have a breastfed infant who can feed from a bottle with previously stored breast milk or formula

Exclusion criteria

Exclusion Criteria:

  • Have a history of inadequate lactation, for multiparous participants who have previously breastfed
  • Have a significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking mirikizumab, or of interfering with the interpretation of data
  • Have any condition that fulfills any stated in the label. All warnings and precautions stated in the label need to be considered
  • Have a history of breast augmentation procedures judged to have a clinical impact on breast milk expression such as breast reduction surgery and some breast implants, or current evidence of acute or chronic conditions affecting breasts and potentially interfering with breast milk collection
  • Have received any (that is, live attenuated) within less than 4 weeks or inactivated vaccine within less than 2 weeks before enrollment or intend to receive a live vaccine during the study or an inactivated vaccine 2 weeks postdose, the mother participant must be given the vaccine at an injection site remote from mirikizumab administration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Other
    Mirikizumab

    Participants will continue to use previously prescribed Mirikizumab administered subcutaneously (SC).

    Drug: Mirikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Concentration of Mirikizumab in Breast Milk

    Time frame: Predose up to 28 Days

Secondary outcomes

  1. Pharmacokinetic (PK): Average Concentration During a Dosing Interval in Steady State of Mirikizumab in Breast Milk

    Time frame: Predose up to 28 Days

  2. Pharmacokinetic (PK): Area Under the Concentration Versus Time Curve Over a Dosing Interval [AUC(0-tau)] of Mirikizumab in Breast Milk

    Time frame: Predose up to 28 Days

  3. Breastfed Infant Safety as Assessed through Measurement of Infant Weight

    Time frame: Predose up to 28 Days

07

Study locations

2 of 20 sites recruiting
  • Northwest Gastroenterologist
    Glenview, Illinois 60026-8000, United States
    Not yet recruiting
    • Nina Merel · Principal investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Not yet recruiting
    • Steven Polyak · Principal investigator
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224-2735, United States
    Not yet recruiting
    • Muniz Pedrogo David · Principal investigator
  • Digestive Disease Medicine of Central New York
    Utica, New York 13502, United States
    Not yet recruiting
    • Harvey Allen · Principal investigator
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Not yet recruiting
    • Angelina Gangestad · Principal investigator
  • GI Research
    Columbia, V6G 2Z6, Canada
    Not yet recruiting
    • Yvette Leung · Principal investigator
  • Aarhus Universitetshospital, Aarhus Sygehus
    Aarhus N, 82000, Denmark
    Not yet recruiting
    • Mette Juelsgaard · Principal investigator
  • Slagelse Hospital
    Slagelse, 4200, Denmark
    Not yet recruiting
    • Natalia Pedersen · Principal investigator
  • Interdisziplinäres Crohn Colitis Centrum Rhein-Main
    Frankfurt am Main, 60594, Germany
    Not yet recruiting
    • Juergen Stein · Principal investigator
  • Klinikum Ernst von Bergmann
    Potsdam, D-14467, Germany
    Not yet recruiting
    • Daniel Baumgart · Principal investigator
  • Rabin Medical Center - PPDS
    HaMerkaz, Israel
    Not yet recruiting
    • Irit Avni-Biron · Principal investigator
  • Shaare Zedek Medical Center
    Jerusalem, 9013102, Israel
    Recruiting
    • Ariella Shitrit · Principal investigator
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
    Not yet recruiting
    • Bella Ungar · Principal investigator
  • Tel Aviv Sourasky Medical Center Ichilov - PPDS
    Tel Aviv, 6423906, Israel
    Recruiting
    • Nathaniel Cohen · Principal investigator
  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Lazio, 00136, Italy
    Not yet recruiting
    • Antonio Gasbarrini · Principal investigator
  • Ospedale San Raffaele S.r.l. - PPDS
    Lombardia, 20132, Italy
    Not yet recruiting
    • Silvio Danese · Principal investigator
  • Ospedale di Rho - UOC Gastroenterologia
    Rho, 20017, Italy
    Not yet recruiting
    • Simone Saibeni · Principal investigator
  • Ospedale Sandro Pertini
    Roma, 00157, Italy
    Not yet recruiting
    • Roberta Pica · Principal investigator
  • DC-MED Micha Kowalski S.K. - ul. Kilinskiego 6
    Radom, 26-610, Poland
    Not yet recruiting
    • Romanowski Janusz · Principal investigator
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 04-501, Poland
    Not yet recruiting
    • Jaroslaw Kierkus · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 25 months after the start.

Of 17 phase 4 interventional studies under Breast Feeding, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612267
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Aug 5, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion